Table 2.
Cell lines |
aCI50 ± SD VPA + 5′-DFUR |
aCI75 ± SD VPA + 5′-DFUR |
aCI90 ± SD VPA + 5′-DFUR |
bDRI at IC50 ± SD VPA 5′-DFUR |
---|---|---|---|---|
HT29 | 0.87 ± 0.17 | 0.75 ± 0.07 | 0.75 ± 0.078 | 1.65 ± 0.35 2.56 ± 0.62 |
SW620 | 0.81 ± 0.10 | 0.83 ± 0.16 | 0.74 ± 0.24 | 2.91 ± 1.49 1.90 ± 0.40 |
HCT-116 | 0.87 ± 0.02 | 0.86 ± 0.04 | 0.77 ± 0.03 | 1.85 ± 0.28 2.44 ± 0.22 |
HCT-116 p53−/− | 1.24 ± 0.15 | 1.15 ± 0.03 | 1.15 ± 0.17 | 1.43 ± 0.24 1.75 ± 0.33 |
aCI values (mean ± SD from at least three separate experiments performed in quadruplicates) computed at 50, 75 and 90% of cell kill (CI50, CI75and CI90, respectively) according by CalcuSyn software after 96 h of treatment. Combinations were considered strongly synergistic when CIs were below 0.9. bDRI values (mean ± SD . from at least three separate experiments performed in quadruplicates) represents the order of magnitude (fold) of dose reduction obtained for IC50 (DRI50) in combination setting compared with each drug alone